The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients

Nitsupa Wattanachai1 & Sutthida Kaewmoongkun1 & Burabha Pussadhamma2 & Pattarapong Makarawate2 & Chaiyasith Wongvipaporn2 & Songsak Kiatchoosakun2 & Suda Vannaprasaht1 & Wichittra Tassaneeyakul1

Received: 15 March 2017 / Accepted: 9 May 2017 / Published online: 26 May 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Purpose The aim of this study was to investigate the contributions of non-genetic and genetic factors on the variability of stable warfarin doses in Thai patients.

Methods A total of 250 Thai patients with stable warfarin doses were enrolled in the study. Demographics and clinical data, e.g., age, body mass index, indications for warfarin and concomitant medications, were documented. Four single nucleotide polymorphisms in the VKORC1 −1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829 genes were detected from gDNA using TaqMan allelic discrimination assays.

Results The patients with variant genotypes of VKORC1 −1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006). In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers. Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%). In contrast, VKORC1 −1639G > A, CYP2C9*3, CYP4F2 rs2108622 genotypes and non-genetic factors accounted for 51.3% of dose variability.

Conclusions VKORC1 −1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses. In contrast, the UGT1A1 rs887829 polymorphism did not contribute to dose variability.

Keywords Non-genetic factors • CYP2C9 • CYP4F2 • VKORC1 • UGT1A1 • Warfarin

Introduction

Warfarin is a widely used oral anticoagulant for the prevention and treatment of various thromboembolic diseases including atrial fibrillation, heart valve replacement, pulmonary embolism, and deep vein thrombosis [1]. Due to its narrow therapeutic index and the large inter-individual variation of warfarin response, dosing may result in serious complications associated with bleeding or thromboembolism [2]. Several genetic and non-genetic factors, e.g., age and body mass index, have been reported to be associated with warfarin dose requirements [3]. Genetic polymorphisms are involved in both the pharmacokinetics and pharmacodynamics of warfarin and, therefore, appear to play an important role in the inter-individual variability of warfarin doses [4]. Two important genes have been identified as being responsible for warfarin treatment, including cytochrome P450 2C9 (CYP2C9) and the vitamin K epoxide reductase complex subunit 1 (VKORC1) [5]. CYP2C9 gene encodes the CYP2C9 enzyme, which is
the main metabolizing enzyme of S-warfarin. The *CYP2C9*<sup>2</sup> and *CYP2C9*<sup>3</sup> variants have been shown to have decreased enzymatic activity, which partly accounts for the variance in warfarin dose requirements [5]. Previous studies in several different ethnic groups, including Thai, have shown that patients with the *CYP2C9*<sup>2</sup> or *CYP2C9*<sup>3</sup> allele required lower warfarin doses than those patients with the *CYP2C9*<sup>1</sup> allele [6–8]. The *VKORC1* gene encodes the VKORC1 enzyme, which is the target enzyme of warfarin action. As reported in several of these ethnic groups, the promoter polymorphism in *VKORC1*-1639G > A, which is, in turn, associated with reduced VKORC1 messenger ribonucleic acid expression, results in the requirement for a lower warfarin dose [7, 9, 10]. The previous studies in several different ethnic groups including Thai populations have reported that patients with single or double variant alleles of *VKORC1*-1639G > A or/and *VKORC1* 1173C > T required significantly lower warfarin doses compared to patients carrying the wild-type allele [4, 8, 11–13].

A previous study reported that CYP4F2, a vitamin K oxidase enzyme, was involved in the metabolism of vitamin K to hydroxyvitamin K [14]. The carriers of the *CYP4F2* rs2108622 variant allele may have a reduced capacity to metabolize vitamin K and, therefore, require a higher warfarin dose to obtain the same anticoagulant response [15]. The previous studies suggest that *CYP4F2* rs2108622 plays a minor role in warfarin dosage requirement in Caucasians and Asians but not African Americans [3, 16, 17]. In comparison with *CYP2C9* and *VKORC1*, there are a limited number of studies that investigated the effect of *CYP4F2* polymorphism on the warfarin dose requirement in Asians. Recently, the polymorphisms of uridine diphosphate-glucuronosyltransferase 1A1 (*UGT1A1*) rs8175347 and rs887829, which are in linked disequilibrium, were significantly associated with a requirement for higher warfarin doses in Korean and Brazilian patients [18, 19]. The carriers of homozygous *UGT1A1* rs8175347 and rs887829 variant alleles are classified as poor metabolizers [20]. Also, 7-hydroxywarfarin, the major metabolite of warfarin, is conjugated by UGT1A1, which is the phase II drug metabolizing enzyme of warfarin [21]. Therefore, variations in UGT1A1 activity may change the levels of 7-hydroxywarfarin. This previous study has reported that 7-hydroxywarfarin acts as the competitive inhibitor of recombinant CYP2C9 metabolism of S-warfarin [22]. Therefore, variations in 7-hydroxywarfarin levels may affect the metabolism of S-warfarin. There are few reported data on the association between *UGT1A1* polymorphisms and warfarin doses among multi-ethnic patient populations. Therefore, further study is required to elucidate the impact of *UGT1A1* polymorphisms on warfarin dose requirements in different ethnic groups.

Taken together, non-genetic factors and two main genetic factors, *VKORC1* and *CYP2C9*, only explain approximately 57–58% of the variability in warfarin dosage. Age, weight, height, smoking and interacting medications accounted for less than 20% of the variance [3]. More than 40% of the variance in the warfarin dose requirement remains unaccounted for. Therefore, further studies on additional factors contributing to the unexplained variation are required. Although many studies have investigated the genetic polymorphisms of *CYP2C9*<sup>3</sup> and *VKORC1* on the warfarin dose requirements, only a few studies simultaneously characterized the effects of all drug metabolizing enzymes in the warfarin metabolic pathway and non-genetic factors in the same cohort study. Thus, the objective of this study was carried out to determine whether non-genetic and genetic factors of relevant drug metabolizing enzymes were involved in warfarin metabolism (*CYP2C9*<sup>3</sup> and *UGT1A1* rs887829), site of action (*VKORC1*-1639G > A), and vitamin K metabolism (*CYP4F2* rs2108622).

## Materials and methods

### Patients

A total of 250 patients at The Queen Sirikit Heart Center of Northeast Thailand and Srinagarind Hospital of the Faculty of Medicine, Khon Kaen University who had stable doses of warfarin, were retrospectively recruited from the outpatient clinic during 2015–2016. Indications for warfarin in these patients were atrial fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension. The inclusion criteria of study subjects included: (1) Thai patients were at least 18 years of age; (2) the international normalized ratio (INR) target range was 2.0–3.0; (3) stable weekly doses (SWDs) of warfarin were defined as the constant dose taken at two consecutive clinical visits for at least 1 month within a target INR range of 2–3; (4) patients who had a measured INR that deviated from the target range by ≤0.2 INR units and that did not result in a change in stable warfarin doses were enrolled in the study. Exclusion criteria included: (1) pregnant patients; (2) patients who had laboratory tests showing abnormal liver function tests (AST, ALT ≥3fold the upper limit of normal); (3) patients suffering from thyroid disorders. The study was approved by The Khon Kaen University Ethics Committee for Human Research (HE581068). Written informed consent was obtained from all patients.

### Data collection

The medical records were reviewed. Demographic variables, i.e., gender, age, height, body weight, and body mass index (BMI) and clinical variables, i.e., indications for warfarin, SWDs of warfarin, INR values, concomitant medications, concomitant diseases, alcohol drinking, and smoking status...
were recorded. Current age was age at the last monitoring point while other covariates such as height, body weight, BMI, comorbidity, and concurrent medications were noted from the stable warfarin dose period.

**Genotyping**

Genomic DNAs of study patients were extracted from peripheral blood using QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). Genotyping of VKORCI (−1639G > A; rs9923231; assay ID C_30403261_20), CYP2C9*3 (1075A > C; rs1057910; assay ID: C_27104892_10), CYP4F2 (1347C > T; rs2108622; assay ID C_16179493_40), and UGT1A1 (rs887829; assay ID C_2669357_10) was performed by the Taqman allelic discrimination assay using a 7500HT Applied Biosystems thermal cycler (Applied Biosystems, CA, USA).

**Statistical analysis**

Deviations from the Hardy–Weinberg equilibrium (HWE) were tested using a chi-square goodness-of-fit analysis. A *p* value of less than 0.01 was assumed to indicate a deviation from HWE. Univariate and multivariate analyses were performed to compare the association of non-genetic factors, e.g., demographic and clinical variables and genetic single nucleotide polymorphisms (SNPs) of interest with stable warfarin doses. Associations between stable warfarin doses and age, weight, height, BMI, and mean INR were evaluated using the Spearman’s correlation. The Mann-Whitney *U* test was used to compare the mean values of warfarin SWDs between two groups. The Kruskal–Wallis *H* test was used to determine associations between the mean values of warfarin SWDs of the three different genotype groups.

Multiple linear regression analysis was used to investigate the factors that independently affected the inter-individual variability of warfarin dose requirements. The variables from univariate analysis with *p* < 0.05 were entered into the multiple linear regression model. In addition, the variables from univariate analyses with *p* > 0.05 (e.g., current smoking status and CYP4F2 rs2108622 genotype) were entered into the multiple linear regression model. Stepwise selections of variables were entered into the regression method including non-genetic and genetic variables that met the default criteria of *p* < 0.05 for entry and *p* > 0.1 for removal. A 5% two-tailed significance level was used in all tests, and the *p* value of <0.05 was considered significantly different. The relative contributions of non-genetic and genetic factors to the total variability of warfarin dose demands were estimated according to the cumulative square of the correlation coefficient (*R*²). The final *R*² of the model indicates the joint contribution of all variables to the variability in therapeutic warfarin dose requirements. The contribution of each factor was calculated as the difference of consecutive cumulative *R*² of each variable. All analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

Demographic and clinical characteristics of 250 patients (129 men and 121 women) are summarized in Supplementary Table 1. The average age of these patients was 60.7 ± 12.8 years (range 22.0–87.0 years). BMI values varied between 14.7 and 43.3 kg/m²; the average BMI was 24.2 kg/m². The average SWDs of warfarin was 22.3 ± 9.2 mg. The average INR of all patients was 2.42 ± 0.28. The most common indication for warfarin therapy was atrial fibrillation (67.2%). Over 45% of the study subjects had co-morbid chronic diseases including hypertension, diabetes mellitus, dyslipidemia, and congestive heart failure. From univariate analysis, age, BMI, amiodarone use, antiplatelet drug use, e.g., clopidogrel, prasugrel, and ticagrelor, atrial fibrillation, and deep vein thrombosis/pulmonary embolism/chronic thromboembolic pulmonary hypertension were found to be significantly associated with SWDs of warfarin (*p* < 0.05) (Supplementary Table 1). Gender had no significant effect on SWDs of warfarin (*p* = 0.998) (Supplementary Table 1).

The patients were stratified into four age groups (Table 1). The study results indicated that the patients older than 60 years required significantly lower warfarin SWDs as compared with those in the group of 20–39 years. In contrast, the patients in the group of 40–59 years did not significantly require higher warfarin SWDs than those in the group of 20–39 years (Table 1). Patients’ INR values in the groups of 40–59, 60–79, and 80–99 years were not significantly different from those in the group of 20–39 years (data not shown). Based on the patients’ BMI, patients with class I and II obesity (30–39.9 kg/m²) required a significantly 24.9% higher SWDs of warfarin as compared with normal weight patients (Table 1). In contrast, the averages of warfarin SWDs received in the patients who were underweight (<18.5 kg/m²), overweight (25–29.9 kg/m²), and class III obesity (morbidly obese) (≥40 kg/m²) were not significantly different from normal weight patients (Table 1).

The non-parametric Spearman-rank correlation analysis of the data revealed that the stable weekly warfarin doses were significantly negatively correlated with age (*r* = −0.332; *p* < 0.001) consistent with the results of the above-mentioned analyses. In contrast, the stable weekly warfarin doses were significantly positively correlated with body weight (*r* = 0.239; *p* < 0.001), BMI (*r* = 0.224; *p* < 0.001). Height and mean INR had no significant correlations with the stable weekly warfarin doses (*r* = 0.111; *P* = 0.81 and *r* = −0.008; *p* = 0.905) (data not shown).
Frequencies of the alleles and genotypes of polymorphisms for VKORC1, CYP2C9, CYP4F2, and UGT1A1 genes are summarized in Table 2. According to the χ² test for goodness of fit, these four SNPs including VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829 were in HWE at a p < 0.01 criterion (data not shown). The comparisons of warfarin SWDs among those patients with different genotypes are shown in Table 2. Patients with AA and GA genotypes of VKORC1 − 1639G > A required 49.7% and 27.7% significantly lower averages of SWDS of warfarin as compared with those with wild-type GG genotype (p < 0.001). The averages of warfarin SWDs were 64.6% and 34.1% lower in CYP2C9*3/*3 and *1/*3 patients than in *1/*1 patients (p = 0.006). The dosage requirement differences, however, were not observed in patients with variant genotypes of CYP4F2 rs2108622 and UGT1A1 rs887829 (p = 0.172 and p = 0.921) (Table 2).

A multiple linear regression model using the predictors including VKORC1 − 1639G > A, CYP2C9*3, and CYP4F2 rs2108622, age, BMI, antiplatelet drug use, amiodarone use, current smoking status explained 51.3% of individual differences in the stable warfarin doses (Table 3). Increasing age, concomitant use of antiplatelet drugs, amiodarone use, variant genotypes of CYP2C9*3, and VKORC1 − 1639G > A were negatively associated with warfarin dose requirements; while increased BMI, current smoker status, and the TT variant genotype of CYP4F2 rs2108622 showed positive correlations. The warfarin SWDs were decreased by 9.7 mg and 18.1 mg in the patients with GA and AA genotypes of VKORC1 − 1639G > A as compared with those with wild-type GG genotype (p < 0.001) (Table 3). Similarly, the warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with CYP2C9*1/*3 and CYP2C9*3/*3 genotypes as compared with those with wild-type *1/*1 genotype (p < 0.001) (Table 3). According to age, warfarin SWDs were decreased by 0.25 mg with each year of aging (p < 0.001) (Table 3). For co-medications, warfarin SWDs were decreased by 7.2 mg and 3.4 mg in the patients receiving amiodarone and antiplatelet drugs together with warfarin (p < 0.001 and p = 0.021) (Table 3), whereas, warfarin SWDs were increased by 0.3 mg for each 1-point increase in BMI. In addition, warfarin SWDs were increased by 4.1 mg in the patients with the TT variant genotype of CYP4F2 rs2108622 as compared with those with the wild-type CC genotype (p = 0.016) (Table 3). Similarly, warfarin SWDs were increased by 3.9 mg in current smokers as compared with non-current smokers (Table 3).

### Discussion

Results from the present study suggest that genetic factors, including CYP2C9*3, CYP4F2 rs2108622, and VKORC1 − 1639G > A genotypes and non-genetic factors with age, BMI, amiodarone use, antiplatelet drug use, and current smoking explained 51.3% of the variability in warfarin dose requirements. The present study is the first study to simultaneously evaluate the effects of genetic polymorphisms of all drug metabolizing enzymes that are responsible for warfarin metabolism (CYP2C9 and UGT1A1), site of action (VKORC1), and vitamin K metabolism (CYP4F2) on warfarin dose requirements in Thai patients. Apart from VKORC1 and CYP2C9 genes, these results showed that the CYP4F2 gene also contributed to warfarin dose requirements in Thais at a modest level, whereas UGT1A1 did not contribute to warfarin dose variability.

In this study, it confirmed the previous findings that VKORC1 − 1639G > A and CYP2C9*3 were the major genetic determinants of warfarin dose requirements, with CYP4F2 having a smaller effect [3, 23, 24]. This also confirmed the previous studies that at 26.2% of the warfarin dose

| Age/BMI category | Age (years)/BMI (kg/m²) | Number (%) | Stable weekly dose (mg) | p value |
|------------------|-------------------------|------------|-------------------------|---------|
|                  | Mean ± SD (range)       |            | Mean ± SD (range)       |         |
| 20–39 years      | 32.1 ± 4.5 (22.0–38.0)   | 15 (6.0)   | 28.0 ± 12.4 (8.0–52.5)  | -       |
| 40–59 years      | 51.2 ± 5.5 (41.0–59.0)   | 88 (35.2)  | 24.6 ± 9.4 (6.0–55.0)   | 0.193   |
| 60–79 years      | 67.9 ± 5.5 (60.0–79.0)   | 133 (53.2) | 20.8 ± 8.3 (5.3–43.8)   | 0.021*  |
| 80–99 years      | 82.5 ± 2.6 (80.0–87.0)   | 14 (5.6)   | 15.0 ± 6.1 (10.5–28.0)  | 0.005*  |
| Underweight      | 17.3 ± 1.0 (14.7–18.4)   | 26 (10.4)  | 18.9 ± 9.2 (6.0–42.0)   | 0.158   |
| Normal weight    | 22.4 ± 1.7 (18.5–24.9)   | 131 (52.4) | 21.3 ± 8.7 (5.3–50.0)   | -       |
| Overweight       | 26.9 ± 1.4 (25.0–29.6)   | 69 (27.6)  | 23.7 ± 9.3 (6.0–55.0)   | 0.077   |
| Obese (class I & II) | 32.0 ± 1.9 (30.2–37.2) | 20 (8.0)  | 26.6 ± 8.2 (13.5–45.0)  | 0.008** |
| Obese (class III) | 41.6 ± 1.4 (40.0–43.3)  | 4 (1.6)    | 30.5 ± 17.8 (10.5–52.5) | 0.266   |

* P values < 0.05 are based on comparisons of the mean warfarin SWDs to the age group of 20–39 years

** P values < 0.05 are based on comparisons of the mean warfarin SWDs to normal weight
variance (22.5% from VKORC1 (−1639G > A) AA genotype and 3.7% from VKORC1 (−1639G > A) GA genotype) (Table 3) [3, 25], the VKORC1 −1639G > A polymorphism accounted for the largest portion. Multiple linear regression was used to examine the associations between multiple variables and stable weekly warfarin doses at one time by adjusting the confounding factors, e.g., age, BMI, antiplatelet drug use, amiodarone use, current smoking, CYP2C9*3, and CYP4F2 rs2108622, which may affect the VKORC1−1639G > A effects on warfarin dose variance.

The contribution of VKORC1−1639G > A was greater than that of CYP2C9*3, which was similar to those previous reports [6–8]. The present study showed that the CYP2C9*3 allele could explain about 6.0% of the warfarin dose variance (3.3% from CYP2C9*3/*3 and 2.7% from CYP2C9*1/*3) (Table 3). Similarly, as in the previous studies, the predictive contribution of CYP2C9*3 varied from 1.7–5.4% in Asians [7, 26], which was lower when compared with Caucasian populations [3]. A previous study in a Caucasian population reported that defective CYP2C9 alleles explained 16.7% of the variability in warfarin dose (12.9% from CYP2C9*3 and 3.8% from CYP2C9*2) [3]. It is possible that no CYP2C9*2 allelic variant and lower frequencies of the CYP2C9*3 were found in Asians as compared with Caucasians [27] which could explain the lower contribution of the CYP2C9*3 allele in this study. For the CYP4F2 rs2108622 polymorphism, the results revealed that the variant TT genotype was identified as a significant contributor and accounted for a modest part of warfarin dose variability (1.2%) (Table 3). Similarly, the previous studies in Asians and Caucasians reported that the predictive contribution of CYP4F2 rs2108622 varied from 1.4–4.0% [3, 23, 24]. According to the UGT1A1 rs887829 polymorphism, the

Table 2 Differences in stable weekly doses of warfarin among genotypes

| Genotype/Allele       | Number of patients (%) | Stable weekly dose (mg) Mean ± SD | p value |
|-----------------------|------------------------|----------------------------------|---------|
| VKORC1 -1639G > A     |                        |                                  |         |
| **Genotype**          |                        |                                  |         |
| GG                    | 7 (2.8)                | 38.6 ± 8.0                       | <0.001  |
| GA                    | 70 (28.0)              | 27.9 ± 9.0                       |         |
| AA                    | 173 (69.2)             | 19.4 ± 7.5                       |         |
| **Allele**            |                        |                                  |         |
| G                     | 84 (16.8)              | -                                | -       |
| A                     | 416 (83.2)             | -                                | -       |
| CYP2C9                |                        |                                  |         |
| **Genotype**          |                        |                                  |         |
| *1/*1                 | 239 (95.6)             | 22.6 ± 9.2                       | 0.006   |
| *1/*3                 | 10 (4.0)               | 14.9 ± 5.3                       |         |
| *3/*3                 | 1 (0.4)                | 8.0                              |         |
| **Allele**            |                        |                                  |         |
| *1                    | 488 (97.6)             | -                                | -       |
| *3                    | 12 (2.4)               | -                                | -       |
| CYP4F2 rs2108622      |                        |                                  |         |
| **Genotype**          |                        |                                  |         |
| CC                    | 153 (61.2)             | 22.2 ± 10.0                      | 0.172   |
| CT                    | 81 (32.4)              | 21.8 ± 7.4                       |         |
| TT                    | 16 (6.4)               | 25.8 ± 8.4                       |         |
| **Allele**            |                        |                                  |         |
| C                     | 387 (77.4)             | -                                | -       |
| T                     | 113 (22.6)             | -                                | -       |
| UGT1A1 rs887829       |                        |                                  |         |
| **Genotype**          |                        |                                  |         |
| CC                    | 192 (76.8)             | 22.0 ± 9.1                       | 0.921   |
| CT                    | 56 (22.4)              | 23.0 ± 9.6                       |         |
| TT                    | 2 (0.8)                | 22.8 ± 17.3                      |         |
| **Allele**            |                        |                                  |         |
| C                     | 440 (88.0)             | -                                | -       |
| T                     | 60 (12.0)              | -                                | -       |
present results showed that \textit{UGT1A1} rs887829 did not significantly contribute to the variability of the stable warfarin doses (Table 2) which was not consistent with the study of Korean patients [18]. In this Thai study population, MAF of \textit{UGT1A1} rs887829 SNP was similar to the Korean population (12\% vs. 13.2\%) [18]. MAF of \textit{UGT1A1} rs887829 SNP was, however, higher in Caucasians (31\%) and African-Americans (43\%) [28]. Although the MAF of \textit{UGT1A1} rs887829 in this study population is similar to Koreans, the effects of \textit{UGT1A1} rs887829 on warfarin dose requirements between Thais and Koreans were different. The reason for these different results is still not well understood.

In terms of non-genetic factors, these results were similar to those previously reported in the literature [3, 7, 29], namely age, BMI, current smoking status, and use of co-medications. In comparison to genetic factors, non-genetics factors played a less important role to explain the variability in warfarin dose requirements. Among non-genetic factors investigated, age accounted for the largest portion, 10.8\% of the warfarin dose variance (Table 3). Additionally, interacting co-medications including amiodarone and BMI explained 3\% and 2.3\% of the dose variance (Table 3). Furthermore, antiplatelet drug use including clopidogrel, prasugrel, ticagrelor explained up to 1.0\% of the dose variance. These interactions cause a possible increase in the anticoagulation effect of warfarin when combined with antiplatelet effects. Although both amiodarone and antiplatelet drug use, including clopidogrel, prasugrel, ticagrelor, are considered minor contributors; however, this knowledge may help the clinicians in adjusting the dose of warfarin for patients who receive long-term amiodarone or antiplatelet drug treatment. Current smoking, according to present results, was considered a minor contributor to guide warfarin dose adjustment. It is possible that smoking may potentially cause an interaction with warfarin by increasing warfarin clearance through the induction of CYP1A2, which leads to a reduced warfarin effect [29, 30].

In summary, results in this present study show that genetic and non-genetic factors are important in determining the variability in warfarin response. \textit{VKORC1}-1639G > A and \textit{CYP2C9}*3 were the strongest genetic predictors of warfarin doses in Thai patients, with \textit{VKORC1} and \textit{CYP2C9} genetic and non-genetic factors, e.g., age, amiodarone use, and BMI being important clinical predictors. Therefore, a more accurate prediction of warfarin dose requirements needs to take into account both genetic and non-genetic factors. There were inherent limitations to the retrospective study design. Confounding factors could not be controlled, e.g., diet containing vitamin K. Prospective studies are needed to determine whether prediction of optimal warfarin doses is enhanced, and adverse effects are avoided by using genetic (\textit{VKORC1}, \textit{CYP2C9}, \textit{CYP4F2}) and non-genetic factors, e.g., age, amiodarone use, BMI, antiplatelet use, and current smoking status to help guide the selection of a patient’s initial warfarin and maintenance doses.

\textbf{Acknowledgements} Grants from the Thailand Research Fund (TRG5880001) and Faculty of Medicine, Khon Kaen University, Thailand (grant number IN59353) are acknowledged. We would like to...
acknowledge Prof. James A. Will, University of Wisconsin-Madison, for editing the manuscript via Publication Clinic KKU, Thailand.

**Author’s contributions** Participated in research design: Nitsupa Wattanachai, Burabha Pussadhamma, Pattarapong Makarawate, Chaiyasith Wongvipaporn, Songsak Kiatchoosakun, Suda Vannaprasaht, and Wichittra Tassaneeyakul.

Enrolled participants: Nitsupa Wattanachai, Suthida Kaewmoongkun, Burabha Pussadhamma, Pattarapong Makarawate, Chaiyasith Wongvipaporn, and Songsak Kiatchoosakun.

Genotyping and data analysis: Nitsupa Wattanachai and Suthida Kaewmoongkun.

Wrote or contributed to the writing of the manuscript: Nitsupa Wattanachai and Wichittra Tassaneeyakul.

**Compliance with ethical standards**

**Conflicts of interest** The authors declare that they have no conflict of interests.

**Ethical approval** All procedures performed in this study involving human participants were in accordance with the ethical standards of The Khon Kaen University Ethics Committee for Human Research (HE581068).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Hirsh J, Dalen J, Anderson DR et al (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1 Suppl):8S–21S
2. Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7(2):99–111
3. Bourgeois S, Jorgensen A, Zhang EJ et al (2016) A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med 8(1):2
4. Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329–2333
5. Flockhart DA, O’Kane D, Williams MS et al (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10(2):139–147
6. Aquilante CL, Langace TY, Lopez LM et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291–302
7. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63(12):1135–1141
8. Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J (2010) Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet 25(6):531–538
9. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285–2293
10. Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5(4):262–270
11. Lee MT, Chen CH, Chou CH et al (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10(12):1905–1913
12. Lindi NA, Arnett DK, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5):511–526
13. Sermsathanasawadi N, Sritongsathian C, Pongrattanaman N et al (2015) The Influence of VKORC1 polymorphisms on warfarin doses in Thai patients with deep vein thrombosis. J Med Assoc Thail 98(6):549–554
14. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75(6):1337–1346
15. Caldwell MD, Awad T, Johnson JA et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106–4112
16. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012) Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 13(16):1925–1935
17. Danese E, Montagnana M, Johnson JA et al (2012) Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92(6):746–756
18. An SH, Chang BC, Lee KE, Gwak HS (2015) Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves. Cardiovasc Ther 33(6):324–328
19. de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL (2014) Pharmacogenomics of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. Mol Diagn Ther 18(6):675–683
20. Gammal RS, Court MH, Haidar CE et al (2016) Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and Atazanavir prescribing. Clin Pharmacol Ther 99(4):363–369
21. Bratton SM, Mosher CM, Khallouki F et al (2012) Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 340(1):46–55
22. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP (2010) Hydroxywarfarin metabolites potentely inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 23(5):939–945
23. Cen HJ, Zeng WT, Leng XY et al (2010) CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70(2):234–240
24. Pautas E, Moreau C, Gounin-Thibault I et al (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87(1):57–64
25. Lindi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827–3834
26. Ohno M, Yamamoto A, Ono A et al (2009) Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 65(11):1097–1103
27. Xie HG, Prasad HC, Kim RB, Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54(10):1257–1270

28. Vardhanabhuti S, Ribaudo HJ, Landovitz RJ et al (2015) Screening for UGT1A1 genotype in study A5257 would have markedly reduced premature discontinuation of Atazanavir for hyperbilirubinemia. Open Forum Infect Dis 2(3):1–8

29. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodtong T, Piriyanan usorn N (2011) Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 139(5):1130–1139

30. Plowchalk DR, Rowland Yeo K (2012) Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol 68(6):951–960